Please ensure Javascript is enabled for purposes of website accessibility

Why Novavax Stock Is Skyrocketing Tuesday

By George Budwell - Updated May 27, 2020 at 8:50AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Novavax's experimental COVID-19 vaccine has officially entered an early-stage trial.

What happened

Shares of Novavax (NVAX 0.78%), a clinical-stage vaccine company, are poised to continue their amazing run today. The biotech's stock is already up by a noteworthy 20% in pre-market action Tuesday morning.

Novavax's shares are heating up yet again this morning in response to the official start of the combined phase 1/2 trial for the company's COVID-19 vaccine candidate, NVX‑CoV2373. Data from the phase 1 portion of the trial is expected to be released as soon as this July. 

A researcher preparing to inject a minature Earth with a vaccine.

Image source: Getty Images.

So what

Novavax's shares have now gained well over 1,000% since the start of 2020, thanks mainly to the excitement surrounding NVX‑CoV2373. This small-cap biotech, in fact, has been the second-best performing healthcare stock so far this year due to its experimental COVID-19 vaccine.

While all this enthusiasm has certainly been a boon for Novavax and its shareholders, there's still no guarantee that NVX‑CoV2373 will end up in the winner's circle. A number of COVID-19 vaccines are under development at the moment -- several of which are being shepherded by far more experienced and better funded companies. 

Now what

The good news is that this early-stage trial is being funded by the Coalition for Epidemic Preparedness Innovations, so Novavax won't have to divert precious resources away from its late-stage flu vaccine platform in order to pursue this high-value endeavor. That being said, investors may still want to take a cautious approach with this red-hot biotech stock. Novavax's historic run hasn't exactly been fueled by a radical change in its underlying fundamentals, after all.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$51.46 (0.78%) $0.40

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
319%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.